Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine

Frank Porreca; David W Dodick

doi:10.1001/jamaneurol.2023.2335

Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine

JAMA Neurol. 2023 Sep 1;80(9):885-886. doi: 10.1001/jamaneurol.2023.2335.

Authors

Frank Porreca^{1

2}, David W Dodick^{2

3}

Affiliations

¹ Department of Pharmacology, University of Arizona, Tucson.
² Mayo Clinic Arizona, Phoenix.
³ Atria Academy of Science and Medicine, New York, New York.

PMID: 37486684
DOI: 10.1001/jamaneurol.2023.2335

No abstract available

Plain language summary

This Viewpoint describes the relevance of sex-specific differences in the treatment of migraine, including in evidence from trials of CGRP therapeutics, and the clinical implications for decision-making in practice and trial design.

MeSH terms

Calcitonin Gene-Related Peptide
Calcitonin Gene-Related Peptide Receptor Antagonists* / therapeutic use
Humans
Migraine Disorders* / drug therapy

Substances

Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide